Skip navigation
中文
English
DSpace
CRIS
Home
Organizations
Researchers
Research Outputs
Explore by
Organizations
Researchers
Research Outputs
Academic & Publications
Help
中文
English
NTU Scholars
National Taiwan University
/
National Taiwan University Hospital
/
National Taiwan University Cancer Center (NTUCC)
/
Medical Oncology-NTUCC
BIN-CHI LIAO
Network Lab
View Statistics
Email Alert
RSS Feed
Information
Publications
29
Project
3
Publications
(All)
All
Articles
Review
Books & Book Chapters
Others
Show/Hide filters
Author
6
chia-chi lin
2
jih-hsiang lee
2
liao b.-c;lin c.-c;chih-hsin yang
1
griesing s.
1
jin-yuan shih
1
liao b.-c;griesing s;chih-hsin yang
1
liao b.-c;lin c.-c;lee j.-h;chih-hsin yang
1
liao b.c;lin c.c;shih j.y;chih-hsin yang
Subject
6
[sdgs]sdg3
1
2 [[2 (isopropylsulfonyl)phenyl]amino] 4 [[2 methoxy 4 [4 (4 methyl 1 piperazinyl) 1 piperidinyl]phenyl]amino] 1,3,5 triazine; 6 amino 5 [1 (2,6 dichloro 3 fluorophenyl)ethoxy] n [4 (4 methyl 1 piperazinylcarbonyl)phenyl] 3 pyridazinecarboxamide; alectinib; anaplastic lymphoma kinase; anaplastic lymphoma kinase inhibitor; cep 37440; ceritinib; crizotinib; entrectinib; ganetespib; luminespib; onalespib; pf 06463922; retaspimycin; tsr 011; unclassified drug; [2 [[5 chloro 2 [[4 [4 (dimethylamino) 1 piperidinyl] 2 methoxyphenyl]amino] 4 pyrimidinyl]amino]phenyl]dimethylphosphine oxide; advanced cancer; cancer resistance; cancer therapy; central nervous system metastasis; fluorescence in situ hybridization; food and drug administration; human; japan; non small cell lung cancer; priority journal; review; treatment outcome
1
afatinib; bemcentinib; buparlisib; capmatinib; crizotinib; dacomitinib; dubermatinib; emibetuzumab; epidermal growth factor receptor; epidermal growth factor receptor 2; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; kelch like ech associated protein 1; luminespib; mammalian target of rapamycin; mitogen activated protein kinase; necitumumab; osimertinib; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; programmed death 1 ligand 1; protein tyrosine kinase; raf protein; ras protein; savolitinib; selumetinib; tepotinib; tivantinib; trastuzumab emtansine; unindexed drug; akt signaling; akt/mtor signaling; cancer combination chemotherapy; cancer immunotherapy; cancer resistance; cancer staging; cell transformation; clinical trial (topic); decreased appetite; dermatitis; diarrhea; epithelial mesenchymal transition; fatigue; fever; fluorescence in situ hybridization; gene dosage; gene mutation; gene overexpression; human; hypoalbuminemia; immunohistochemistry; liquid biopsy; neutropenia; next generation sequencing; non small cell lung cancer; nonhuman; peripheral edema; pi3k/akt signaling; pneumonia; priority journal; progression free survival; review; stomatitis; treatment duration; treatment response
1
afatinib; bevacizumab; carboplatin; cisplatin; dacomitinib; docetaxel; epidermal growth factor receptor; erlotinib; gefitinib; gemcitabine; hydroxychloroquine; olaparib; paclitaxel; pemetrexed; acne; anemia; anorexia; cancer combination chemotherapy; cancer survival; dermatitis; diarrhea; drug efficacy; drug eruption; drug safety; exon; fatigue; gene mutation; gene sequence; histology; human; interstitial lung disease; lung adenocarcinoma; lung non small cell cancer; medline; monotherapy; neutropenia; overall survival; paronychia; phase 2 clinical trial (topic); phase 3 clinical trial (topic); polymerase chain reaction; progression free survival; quality of life; rash; review; side effect; survival rate; survival time; treatment failure; treatment response; adenocarcinoma; antineoplastic agents; carcinoma, non-small-cell lung; clinical trials, phase iii as topic; female; humans; lung neoplasms; male; mutation; protein kinase inhibitors; receptor, epidermal growth factor; risk factors; sex factors; treatment outcome
1
afatinib; cetuximab; cytotoxic agent; epidermal growth factor receptor; erlotinib; gefitinib; naquotinib; nazartinib; olmutinib; osimertinib; protein tyrosine kinase inhibitor; rociletinib; antineoplastic agent; epidermal growth factor receptor; protein kinase inhibitor; scatter factor receptor; cancer chemotherapy; cancer combination chemotherapy; cancer survival; cancer therapy; disease course; gene amplification; gene mutation; human; information retrieval; liquid biopsy; lung biopsy; medline; non small cell lung cancer; priority journal; review; tumor biopsy; algorithm; disease exacerbation; disease management; drug development; genetics; lung tumor; molecularly targeted therapy; mutation; non small cell lung cancer; pathology; treatment outcome; algorithms; antineoplastic agents; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; disease management; disease progression; drug discovery; gene amplification; humans; lung neoplasms; molecular targeted therapy; mutation; protein kinase inhibitors; proto-oncogene proteins c-met; receptor, epidermal growth factor; treatment outcome
1
alectinib; anaplastic lymphoma kinase inhibitor; atezolizumab; azd 3759; ceritinib; crizotinib; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; nivolumab; osimertinib; pembrolizumab; unclassified drug; abc transporter subfamily b; antineoplastic agent; epidermal growth factor receptor; protein kinase inhibitor; brain metastasis; brain radiation; cancer chemotherapy; cancer patient; human; local therapy; medline; non small cell lung cancer; prospective study; review; systemic therapy; antagonists and inhibitors; brain tumor; clinical trial (topic); drug resistance; genetics; lung tumor; metabolism; mutation; non small cell lung cancer; pathology; secondary; antineoplastic agents; atp binding cassette transporter, sub-family b; brain neoplasms; carcinoma, non-small-cell lung; clinical trials as topic; drug resistance, neoplasm; humans; lung neoplasms; mutation; protein kinase inhibitors; receptor, epidermal growth factor
Date issued
1
2019
1
2018
2
2017
1
2016
1
2015
1
2013
Fulltext
7
no fulltext
Close filters
Refined By:
Author:
chih-hsin yang
Author:
bin-chi liao
Type:
review
Results 1-7 of 7 (Search time: 0.045 seconds).
Issue Date
Title
Author(s)
Source
scopus
WOS
Fulltext/Archive link
1
2019
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
BIN-CHI LIAO
; Griesing S.; CHIH-HSIN YANG
Therapeutic Advances in Medical Oncology
27
25
2
2018
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
BIN-CHI LIAO
; CHIA-CHI LIN
; CHIH-HSIN YANG
Expert Opinion on Pharmacotherapy
5
5
3
2017
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
BIN-CHI LIAO
; CHIA-CHI LIN
; CHIH-HSIN YANG
Current Oncology Reports
19
19
4
2017
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
BIN-CHI LIAO
; Chia-Chi Lin
; JIH-HSIANG LEE
; CHIH-HSIN YANG
Lung Cancer
38
35
5
2016
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
BIN-CHI LIAO
; CHIA-CHI LIN
; JIH-HSIANG LEE
; CHIH-HSIN YANG
Journal of Biomedical Science
43
37
6
2015
Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
BIN-CHI LIAO
; CHIA-CHI LIN
; JIN-YUAN SHIH
; CHIH-HSIN YANG
Therapeutic Advances in Medical Oncology
16
16
7
2013
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
BIN-CHI LIAO
; CHIA-CHI LIN
; CHIH-HSIN YANG
Drugs
16
16
Claim Researcher Page
Login via ORCID to claim this profile:
ORCID Login
Contact via feedback form
If you want contact administrator site clicking the follow button